Table A2.
Studies Examining the Role of Irradiation After Breast-Conserving Surgery
| Study | No. of Patients | Follow-Up (years) | Age (years) | Tumor Size (cm) | Treatment | Local Recurrence | Statistical Significance |
|---|---|---|---|---|---|---|---|
| CALGB 9343 | 636 | 10.5 | ≥ 70 | ≤ 2.0 | Tam | 9 | < .001* |
| TamRT | 2 | ||||||
| NSABP B211 | 1,009 | 8 | Any age | < 1 | Tam | 17 | < .001 |
| TamRT | 3 | ||||||
| RT placebo | 9 | ||||||
| Winzer et al5 | 361† | 10 | 45-75 | ≤ 2 | Surgery alone | 34 | < .001 |
| Surgery plus RT | 10 | ||||||
| Surgery + tamoxifen | 8 | ||||||
| Surgery + RT + tamoxifen | 9 | ||||||
| Potter et al4 | 869 | 4.5 | Postmenopausal (mean, 66) | ≤ 3 | Tam or AI | 6 | < .001 |
| Tam or AI + RT | 2 | ||||||
| Fyles et al3 | 769 | 5.6 | > 50 | ≤ 5 | Tam | 8 | .001 |
| TamRT | 1 | ||||||
| Tinterri et al10 | 749 | 5.0 | 55-75 | < 2.5 | Surgery alone | 3 | .07 |
| Surgery + RT | 1 | ||||||
| Forrest et al‡ | 585 | 6 | < 70 | ≤ 4 | Tam§ | 25 | NS |
| TamRT | 6 |
Abbreviations: AI, aromatase inhibitor; CALGB, Cancer and Leukemia Group B; NS, not stated; NSABP, National Surgical Adjuvant Breast and Bowel Project; RT, radiation therapy; Tam, tamoxifen alone; TamRT, tamoxifen plus radiation therapy.
*
Locoregional recurrence.
†
347 analyzed.
‡
Forrest et al: Lancet 348:708-713, 1996.
§
Or cyclophosphamide, methotrexate, and fluorouracil based on estrogen receptor status.